CPTCF (Cytophage Technologies) EBIT : $-2.43 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies EBIT?

Cytophage Technologies's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-0.79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.43 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cytophage Technologies's annualized ROC % for the quarter that ended in Sep. 2024 was -126.10%. Cytophage Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -133.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cytophage Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -49.35%.

Cytophage Technologies EBIT Historical Data

The historical data trend for Cytophage Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies EBIT Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

EBIT

-2.50

-0.55

-0.10

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial					-0.72	2.39	-3.15	-0.89	-0.79

Competitive Comparison of Cytophage Technologies's EBIT

For the Biotechnology subindustry, Cytophage Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Cytophage Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.43 Mil.

Cytophage Technologies (GREY:CPTCF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cytophage Technologies's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-3.244 * ( 1 - 0% )	/	( (2.506	+	2.639)	/ 2 )
=	-3.244	/	2.5725
=	-126.10 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.336	-	0.3	-	( 2.667	-	max(0, 0.518	-	3.048	+	2.667	))
=	2.506

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.531	-	0.278	-	( 1.735	-	max(0, 0.498	-	2.112	+	1.735	))
=	2.639

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cytophage Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.14	/	( ( (2.288 + max(-0.079, 0))	+	(2.419 + max(-0.076, 0)) )	/	2 )
=	-3.14	/	( ( 2.288	+	2.419 )	/	2 )
=	-3.14	/	2.3535
=	-133.42 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.12	+	0	+	0.102)	-	(0.3	+	0	+	0.001)
=	-0.079

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.123	+	0	+	0.079)	-	(0.278	+	0	+	0)
=	-0.076

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cytophage Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-2.433	/	4.930
	=	-49.35 %

Cytophage Technologies EBIT Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (GREY:CPTCF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

CYTO:Canada

Address

26 Henlow Bay, Winnipeg, MB, CAN, R3Y 1G4

Website

https://www.cytophage.com

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.